In recent years, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as cornerstone therapies in the management of T2D and obesity [5,6,7]
Does this mean there is no value in products claiming to increase GLP-1
While extensively studied modification sites such as H3K18 have been well-characterized across various pathological conditions [20, 37, 65], investigation of other histone sites remains insufficient
This dual hypertrophic-and-hyperplastic mechanism is frequently cited as what distinguishes IGF-1 LR3 from single-pathway anabolic compounds in comparative research
However, skeletal muscle-specific carnitine palmitoyltransferase 2 (CPT2)-deficient mice accumulate large amounts of acylcarnitine in muscle and plasma and still preserve insulin sensitivity [75], highlighting the role of acylcarnitine only as an indicator of FAO rather than as a direct mediator of insulin resistance [76]